サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1798352

基礎インスリンの世界市場

Basal Insulin

出版日
ページ情報
英文 179 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
基礎インスリンの世界市場
出版日: 2025年08月26日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 179 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

基礎インスリンの世界市場は2030年までに3億2,220万米ドルに達する見込み

2024年に2億6,550万米ドルと推定される基礎インスリンの世界市場は、2030年には3億2,220万米ドルに達し、分析期間2024～2030年のCAGRは3.3%で成長すると予測されます。本レポートで分析したセグメントの1つであるランタスインスリンは、CAGR 2.3%を記録し、分析期間終了時には1億190万米ドルに達すると予測されます。Levemir Insulinセグメントの成長率は、分析期間中CAGR 4.6%と推定されます。

米国市場は7,230万米ドルと推定され、中国はCAGR 5.9％で成長すると予測される

米国の基礎インスリン市場は、2024年に7,230万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを5.9%として、2030年までに6,310万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4％と2.5％と予測されています。欧州では、ドイツがCAGR 1.8%で成長すると予測されています。

世界の基礎インスリン市場- 主要動向と促進要因のまとめ

治療パラダイムの変化は糖尿病治療における基礎インスリンの使用にどのような影響を与えているか？

糖尿病治療のパラダイムは大きく変化しており、その中で基礎インスリンは中心的な役割を担っています。基礎インスリンは、長期にわたり安定したインスリン分泌を行うよう設計されており、体内の自然なインスリン分泌を模倣することにより、1型および2型糖尿病のグルコースコントロールをサポートします。GLP-1受容体作動薬やSGLT2阻害薬などの新しい治療薬が注目されている一方で、基礎インスリンは、特に経口抗糖尿病薬のみでは目標値を達成できない患者に対する血糖管理の要であり続けています。臨床現場では、高血糖の長期化に伴う合併症を予防するために、基礎インスリンの早期投与を重視する医師が増えています。インスリングラルギン、インスリンデテミル、インスリンデグルデクのような最新の基礎インスリンアナログは、より予測可能な薬物動態を示し、夜間低血糖のリスクを低減し、1日1回の投与によりアドヒアランスを改善します。さらに、糖尿病が進行性の疾患であることが認識されるようになり、治療目標が個別化され、基礎インスリンが患者固有のニーズに合わせた併用レジメンの一部として頻繁に組み込まれるようになりました。世界の2型糖尿病の増加、特に高齢化や座りがちな生活習慣を持つ人々における負担の増大は、長期的な代謝コントロールのための多角的なアプローチの一環として、基礎インスリン治療への継続的な需要を強化しています。

なぜ製剤とデリバリーシステムの進歩が基礎インスリンの採用を促進するのか？

製剤科学とインスリン送達システムの技術的進歩は、多様な患者集団における基礎インスリンの採用と使いやすさを著しく向上させています。次世代の基礎インスリンアナログは、血糖値の変動を最小限に抑えながら、24時間を超える長時間のグルコースコントロールを提供する、超長時間作用プロファイルのために設計されています。これは、不規則なスケジュールを持つ患者や、厳格な投薬タイミングに課題を抱える患者にとって特に有益であることが証明されています。製剤の安定性が向上し、注射部位のばらつきが少なくなったことも、より安定した治療成績に寄与しています。デリバリー面では、ユーザーフレンドリーなインスリンペンやデジタル注射追跡ツールの台頭により、インスリン投与がより身近なものとなり、新規に診断された患者にとって抵抗感がなくなってきています。これらの技術革新は、治療強化の遅れにしばしば関連するインスリン開始に対する認知的・心理的障壁を軽減しています。これと並行して、モバイルヘルスアプリケーションとグルコースモニタリング技術は、基礎インスリン投与とリアルタイムのデータインサイトとの緊密な統合をサポートし、患者やヘルスケアプロバイダーがより多くの情報に基づいた治療調整を行えるようになりました。基礎インスリンのバイオシミラー製品も市場に投入され、品質や有効性を損なうことなく、費用対効果の高い代替品を提供することで、先進国、新興国双方のヘルスケアシステムにおけるアクセスを拡大しています。基礎インスリンは、製品デザインとユーザーエクスペリエンスの両面において、より効果的であるだけでなく、増加する世界の糖尿病患者にとってより近づきやすいものとなっています。

医療政策、市場アクセス、患者教育は、世界の基礎インスリン市場をどのように形成していますか？

医療政策改革、償還メカニズム、患者教育への取り組みは、基礎インスリン治療へのアクセスとアドヒアランスを世界的に形成する上で重要な役割を果たしています。多くの高所得国では、経口薬で不十分な場合の2型糖尿病の第一選択注射療法として、長時間作用型基礎インスリン製剤の使用を支持する保険適用や国の医療計画が増加しています。糖尿病の経済的負担を軽減することを目的とした政策により、同様の治療効果をより低コストで提供するバイオシミラーインスリンアナログの普及が促進されています。しかし、低所得の環境では、経済的な問題や限られたヘルスケアのインフラが原因で、アクセスは依然として課題となっています。世界・ヘルス組織や非営利団体は、価格協定を交渉し、インスリンが十分なサービスを受けていない人々に確実に届くようサプライ・チェーンを支援することで、このギャップを埋めようとしています。特に2型糖尿病患者は、注射や低血糖、治療の失敗を恐れるあまり、インスリン投与開始が遅れがちです。糖尿病教育者による正確な情報とサポートで患者に力を与えることは、早期導入とアドヒアランス向上の鍵となります。各国がデジタルヘルスツールを公衆衛生戦略に統合するにつれて、バーチャルケアと遠隔医療が、漸増投与を通じて患者を指導し、長期的な転帰をモニターするために活用されるようになり、それによってインスリン使用に対する信頼が高まり、集団レベルでの全体的な糖尿病管理が強化されています。

基礎インスリンの世界市場成長の原動力は？

世界の基礎インスリン市場の成長は、疫学的動向、技術の進歩、戦略的市場開拓の組み合わせによって牽引されています。糖尿病、特に2型糖尿病の世界の有病率の上昇は、需要を煽る最も顕著な要因であり、肥満、座りがちな行動、高齢化などのライフスタイル要因がこの急増に大きく寄与しています。このような負担の増大に対応するため、ヘルスケアシステムはインスリン療法、特に血糖目標値の達成と維持に有効性が証明されている基礎インスリンの早期開始と長期的な最適化を優先しています。より平坦な作用プロファイルや持続時間の延長など、薬力学的特性が改善された新規インスリンアナログの発売は、より便利で効果的な選択肢を求める臨床医と患者の双方を惹きつけています。さらに、バイオシミラー基底型インスリンの入手可能性が高まることで、治療へのアクセスが拡大する一方で、メーカー間の競争が激化し、より手頃な価格と幅広い市場への浸透につながっています。製薬企業とデジタルヘルスプラットフォームの提携も、患者のアドヒアランスと実臨床でのアウトカム追跡をサポートする統合糖尿病管理エコシステムを構築しています。さらに、都市化とヘルスケア投資によって患者へのリーチが拡大している新興市場での診断率の拡大も成長を支えています。これらの促進要因を総合すると、基礎インスリン市場は堅固で持続可能な軌道を確立しつつあり、当面は世界の糖尿病治療に不可欠な要素であり続けることが確実です。

セグメント

製品（ランタスインスリン、レベミルインスリン、トウジオインスリン、トレシーバインスリン、バサグラーインスリン）

調査対象企業の例

  • Adocia
  • Biocon Limited
  • Boehringer Ingelheim
  • Dongbao Enterprise Group
  • Eli Lilly and Company
  • Gan & Lee Pharmaceuticals
  • Geropharm
  • Glenmark Pharmaceuticals
  • Julphar（Gulf Pharmaceutical Industries）
  • Merck KGaA（EMD Serono in US/Canada）
  • Mylan N.V.（part of Viatris）
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A.
  • Sandoz（a Novartis division）
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Wockhardt Ltd.
  • Ypsomed Holding AG
  • Zhuhai United Laboratories Co., Ltd.
  • Zydus Lifesciences Ltd.

AI統合

私たちは、検証された専門家のコンテンツとAIツールで市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38555

Global Basal Insulin Market to Reach US$322.2 Million by 2030

The global market for Basal Insulin estimated at US$265.5 Million in the year 2024, is expected to reach US$322.2 Million by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Lantus Insulin, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$101.9 Million by the end of the analysis period. Growth in the Levemir Insulin segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$72.3 Million While China is Forecast to Grow at 5.9% CAGR

The Basal Insulin market in the U.S. is estimated at US$72.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$63.1 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Basal Insulin Market - Key Trends & Drivers Summarized

How Are Shifting Treatment Paradigms Influencing the Use of Basal Insulin in Diabetes Care?

The landscape of diabetes management has been undergoing significant transformation, and basal insulin continues to play a central role in these evolving treatment paradigms. Designed to provide a steady release of insulin over a prolonged period, basal insulin supports glucose control in both type 1 and type 2 diabetes by mimicking the body’s natural background insulin secretion. While newer therapies such as GLP-1 receptor agonists and SGLT2 inhibitors are gaining attention, basal insulin remains a cornerstone in glycemic management, especially for patients who fail to achieve targets with oral antidiabetic drugs alone. In clinical practice, physicians increasingly emphasize early initiation of basal insulin to prevent complications related to prolonged hyperglycemia. Modern basal insulin analogs like insulin glargine, insulin detemir, and insulin degludec offer more predictable pharmacokinetics, reduced risk of nocturnal hypoglycemia, and improved adherence due to once-daily dosing. Additionally, the recognition of diabetes as a progressive condition has shifted treatment goals toward individualized care, where basal insulin is frequently integrated as part of combination regimens tailored to patient-specific needs. The growing burden of type 2 diabetes worldwide, particularly in aging populations and those with sedentary lifestyles, reinforces the ongoing demand for basal insulin therapy as part of a multifaceted approach to long-term metabolic control.

Why Are Advancements in Formulation and Delivery Systems Enhancing Basal Insulin Adoption?

Technological progress in formulation science and insulin delivery systems is significantly enhancing the adoption and usability of basal insulin across diverse patient populations. Next-generation basal insulin analogs are being engineered for ultra-long action profiles, offering extended glucose control beyond 24 hours with minimal fluctuations in blood sugar levels. This has proven particularly beneficial for patients with irregular schedules or those who face challenges with rigid medication timing. Improved formulation stability and lower injection site variability are also contributing to more consistent therapeutic outcomes. On the delivery front, the rise of user-friendly insulin pens and digital injection tracking tools is making insulin administration more accessible and less intimidating for newly diagnosed patients. These innovations reduce the cognitive and psychological barriers to insulin initiation, a factor often associated with delayed treatment intensification. In parallel, mobile health applications and glucose monitoring technologies now support tighter integration of basal insulin dosing with real-time data insights, helping patients and healthcare providers make more informed treatment adjustments. Biosimilar versions of basal insulin have also entered the market, offering cost-effective alternatives without compromising quality or efficacy, thus expanding access in both developed and emerging healthcare systems. These ongoing innovations in both product design and user experience are making basal insulin not only more effective but also more approachable for the growing global diabetic population.

How Are Health Policy, Market Access, and Patient Education Shaping the Global Basal Insulin Market?

Health policy reforms, reimbursement mechanisms, and patient education efforts are playing critical roles in shaping access and adherence to basal insulin therapies globally. In many high-income countries, insurance coverage and national health plans increasingly support the use of long-acting basal insulins as first-line injectable therapy for type 2 diabetes when oral medications are insufficient. Policies aimed at reducing the economic burden of diabetes are facilitating wider adoption of biosimilar insulin analogs, which offer similar therapeutic benefits at a lower cost. In lower-income settings, however, access remains a challenge due to affordability issues and limited healthcare infrastructure. Global health organizations and non-profits are working to close this gap by negotiating pricing agreements and providing supply chain support to ensure that insulin reaches underserved populations. Alongside access efforts, education initiatives are gaining traction to address insulin hesitancy, particularly among type 2 diabetes patients who often delay insulin initiation due to fears of injections, hypoglycemia, or perceived treatment failure. Empowering patients with accurate information and support from diabetes educators is key to improving early adoption and adherence. As countries integrate digital health tools into their public health strategies, virtual care and telemedicine are being leveraged to guide patients through basal insulin titration and monitor long-term outcomes, thereby boosting confidence in insulin use and enhancing overall diabetes control at a population level.

What Is Driving the Growth of the Global Basal Insulin Market?

The growth in the global basal insulin market is being driven by a combination of epidemiological trends, technological advancements, and strategic market developments. The rising global prevalence of diabetes, particularly type 2 diabetes, is the most prominent factor fueling demand, with lifestyle factors such as obesity, sedentary behavior, and aging populations contributing significantly to this surge. In response to this growing burden, healthcare systems are prioritizing the early initiation and long-term optimization of insulin therapy, especially basal insulin, due to its proven efficacy in achieving and maintaining glycemic targets. The launch of novel insulin analogs with improved pharmacodynamic properties, such as flatter action profiles and longer durations, is attracting both clinicians and patients seeking more convenient and effective options. In addition, the increasing availability of biosimilar basal insulins is expanding treatment access while intensifying competition among manufacturers, leading to better affordability and broader market penetration. Partnerships between pharmaceutical companies and digital health platforms are also creating integrated diabetes management ecosystems that support patient adherence and real-world outcome tracking. Growth is further supported by expanding diagnosis rates in emerging markets, where urbanization and healthcare investment are increasing patient reach. Altogether, these drivers are establishing a robust and sustainable trajectory for the basal insulin market, ensuring it remains a vital component of global diabetes care for the foreseeable future.

SCOPE OF STUDY:

The report analyzes the Basal Insulin market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin, Basaglar Insulin)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • Adocia
  • Biocon Limited
  • Boehringer Ingelheim
  • Dongbao Enterprise Group
  • Eli Lilly and Company
  • Gan & Lee Pharmaceuticals
  • Geropharm
  • Glenmark Pharmaceuticals
  • Julphar (Gulf Pharmaceutical Industries)
  • Merck KGaA (EMD Serono in US/Canada)
  • Mylan N.V. (part of Viatris)
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A.
  • Sandoz (a Novartis division)
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Wockhardt Ltd.
  • Ypsomed Holding AG
  • Zhuhai United Laboratories Co., Ltd.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Basal Insulin - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Diabetes Prevalence Throws the Spotlight on Long-Acting Insulin Therapies
    • Shifting Treatment Protocols Spur Demand for Simplified Basal Insulin Regimens
    • Aging Population and Higher Type 2 Diabetes Incidence Expand Addressable Market for Basal Insulin
    • Technological Innovations in Insulin Formulations Strengthen Business Case for Next-Gen Basal Products
    • Growing Emphasis on Glycemic Control with Fewer Hypoglycemia Risks Drives Adoption of Advanced Basal Insulin
    • Here's How Patient-Centric Delivery Devices Accelerate Demand in Home-Based Diabetes Management
    • Health System Pressures to Lower Total Cost of Care Propel Use of Long-Acting Insulin in Public Programs
    • Rising Awareness and Diagnosis Rates Sustain Growth in Underserved and Rural Markets
    • Inclusion of Basal Insulin in National Formularies Expands Market Penetration in Emerging Economies
    • Increasing Use in Combination Therapies Throws the Spotlight on Basal Insulin as a Foundational Treatment
    • Here's the Story: How Biosimilar Basal Insulin is Reshaping Competitive Dynamics and Pricing Models
    • Digital Health Integration with Insulin Delivery Devices Generates Demand for Smart Basal Insulin Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Basal Insulin Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Basal Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Basal Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Basal Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Lantus Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Lantus Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Lantus Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Levemir Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Levemir Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Levemir Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Toujeo Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Toujeo Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Toujeo Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Tresiba Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Tresiba Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Tresiba Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Basaglar Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Basaglar Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Basaglar Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • JAPAN
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • CHINA
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: China 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • EUROPE
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Basal Insulin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Basal Insulin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Basal Insulin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • FRANCE
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: France 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • GERMANY
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: UK 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Spain 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Russia 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Rest of Europe 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Basal Insulin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Basal Insulin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Basal Insulin by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Australia 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • INDIA
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: India 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: South Korea 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Basal Insulin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Basal Insulin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Basal Insulin by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Argentina 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Brazil 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Mexico 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Latin America 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Basal Insulin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Basal Insulin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Basal Insulin by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Iran 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Israel 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Saudi Arabia 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UAE 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Rest of Middle East 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • AFRICA
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Africa 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030

IV. COMPETITION